Published • loading... • Updated
Delphi Diagnostics Announces New Publication in the European Journal of Cancer
The study of 659 PACS-01 samples found EAIRR added statistically significant prognostic and endocrine-predictive information beyond the 21-gene Recurrence Score.
- On Wednesday, Delphi Diagnostics announced new clinical data published in the European Journal validating Recurrence Risk as a significant independent predictor of outcomes for hormone receptor-positive, node-positive breast cancer patients.
- The study demonstrates that EAIRR, also known as SET2,3, provides meaningful prognostic and endocrine-predictive information beyond the 21-gene Recurrence Score, enhancing risk stratification for node-positive patients.
- Researchers analyzed 659 patient samples from the PACS-01 clinical trial, establishing Level 1B evidence that EAIRR refines prognostic risk stratification in node-positive HR+ breast cancer.
- Data indicate EAI strongly predicted benefit from adjuvant endocrine therapy, with interaction values below 0.001, enabling physicians to identify patients sensitive to endocrine treatment for personalized selection.
- Delphi Diagnostics aims to make the EAI test available, opening pathways for personalized breast cancer care, while developer Fraser Symmans maintains a financial relationship with Delphi managed by the Anderson Cancer Center's Interest Committee.
Insights by Ground AI
31 Articles
31 Articles
Coverage Details
Total News Sources31
Leaning Left1Leaning Right1Center19Last UpdatedBias Distribution90% Center
Bias Distribution
- 90% of the sources are Center
90% Center
C 90%
Factuality
To view factuality data please Upgrade to Premium
